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Abstract
The burden of oxidative stress is increased in chronic obstructive pulmonary disease (COPD). However, whether
the intra-cellular mechanisms controlling the oxidant/anti-oxidant balance in structural airway cells such as airway
smooth muscle in COPD is altered is unclear. We sought to determine whether the expression of the NADPH
oxidase (NOX)-4 is increased in airway smooth muscle in COPD both in vivo and primary cells in vitro and its role
in hydrogen peroxide-induced reactive oxygen species generation. We found that in vivo NOX4 expression was
up-regulated in the airway smooth muscle bundle in COPD (n = 9) and healthy controls with >20 pack year history
(n = 4) compared to control subjects without a significant smoking history (n = 6). In vitro NOX4 expression was
increased in airway smooth muscle cells from subjects with COPD (n = 5) compared to asthma (n = 7) and upregulated
following TNF-α stimulation. Hydrogen peroxide-induced reactive oxygen species generation by airway smooth muscle
cells in COPD (n = 5) was comparable to healthy controls (n = 9) but lower than asthma (n = 5); and was markedly
attenuated by NOX4 inhibition. Our findings demonstrate that NOX4 expression is increased in vivo and in vitro in
COPD and although we did not observe an intrinsic increase in oxidant-induced reactive oxygen species generation
in COPD, it was reduced markedly by NOX4 inhibition supporting a potential therapeutic role for NOX4 in COPD.
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Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity and mortality [1–3] with
abnormalities in the oxidant/antioxidant balance being
implicated in its pathogenesis [4]. Increased airway
smooth muscle (ASM) mass is a feature of small airway
disease and is related to airflow obstruction [5–7]. Previ-
ous work in our group has implicated increased nicotina-
mide adenine dinucleotide phosphate (NADPH)-oxidase
type 4 (NOX4) expression in the ASM in the intrinsic
ASM hyper-contractility observed in asthma [8]. Although
oxidant/antioxidant imbalance is believed to be a key
pathogenic factor in COPD [4, 9], little work has currently
been performed to investigate what role, if any, NOX4
plays. Importantly, NOX4 expression is increased by both
TGF-β and TNF-α, which are elevated in the ASM and/or
serum of COPD subjects [10, 11] implicating a potential
for increased NOX4 expression. Therefore, we hypothe-
sized that NOX4 expression is increased in ASM from
subjects with COPD resulting in enhanced reactive oxygen
species (ROS) and oxidative stress.
Subjects with COPD and healthy controls (age-,
sex- and smoking status-matched with normal lung
function) and asthmatics as a disease control were re-
cruited from Leicester, UK. The study was approved by
the Leicestershire Ethics Committee and all patients gave
their written informed consent.
Two-micrometer sections from bronchial submucosal
specimens from subjects with COPD and healthy con-
trols were stained with anti-NADPH oxidase 4 antibody
(rabbit monoclonal, 11 μg/mL; Abcam, Cambridge,
United Kingdom). Staining intensity above isotype
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control was measured in ASM bundles by thresholding
using Cell^F software (Olympus, UK), where the
thresholding levels set on Hue, Saturation and Intensity
scales by an observer blinded to the subjects' clinical
characteristics.
Pure ASM bundles were isolated from bronchoscopic
samples and used at passages 2–6. Real-Time Reverse
Transcription–Polymerase Chain Reaction was performed
(SuperScript Vilo cDNA synthesis kit, Express SYBR
GreenER qPCR Supermix Universal; Invitrogen). Relative
quantification of NOX4 mRNA expression was done using
the comparative 2-ΔΔCt method and expressed as fold
change as previously described [12], with amplification of
18S RNA as the internal normaliser gene (18 s forward
primer ;h18SRNA.891 F:GTTGGTTTTCGGAACTG
AGG, 18 s reverse primer ;h18SRNA.1090R:GCA
TCGTTTATGGTCGGAAC; NOX4 forward primer;
hNox4.598 F:TGGCTGCCCATCTGGTGAATG, and
NOX4 reverse primer; hNox4.878R:CAGCAGCCCTC
CTGAAACATGC. ASM was stained with a NOX4 mono-
clonal Alexa Fluor 488 conjugated antibody (Abcam) with
or without prior incubations with 50 ng/mL TNFα for
24 h. Intracellular reactive oxygen species (ROS) was
assessed by incubating the ASM with 10 mM 5-(and-6)-
chloromethyl-29,79-dichlorodihydrofluorescein diacetate
(DCFDA) [8] in the presence or absence of the NOX4
inhibitor 10 μM (GKT137831 gift from Genkyotex).
Statistical analysis was performed using PRISM Version
6 (GraphPad, La Jolla, CA). Parametric data were pre-
sented as mean (SEM) and nonparametric data as median
(interquartile range). Analysis between groups was by t
tests or Mann–Whitney tests and across groups by
ANOVA or repeated measures ANOVA for paired data
with appropriate post hoc pairwise comparisons. Correl-
ation by Spearman rank test. P < 0.05 was considered
significant.
Representative photomicrographs illustrating NOX4
expression in the ASM are as shown (Fig. 1a). NOX4
ASM expression was increased in the subjects with
COPD and the control subjects with a >20 pack year
smoking history compared to the control subjects
with ≤20 pack year history (21.5 ± 2.9 % and 25.7 ± 3.3
versus 5.9 ± 1.7 % respectively; P < 0.001; Fig. 1b). The
intensity of NOX4 expression was positively correlated
with smoking history in the group as a whole (r = 0.48;
P = 0.037) and healthy controls (r = 0.72; P = 0.019),
but not for the subjects with COPD (r = 0.11; P =
0.785; Fig. 1c).
NOX4 mRNA expression by primary cultured ASM
from COPD subjects was not significantly different to
either healthy controls (P = 0.174; Fig. 1d), nor our
previously published NOX4 mRNA expression by ASM
from asthmatic subjects (data not shown) [8]. We have
reported that NOX4 protein expression as measured by
flow cytometry was elevated in ASM from asthmatic
compared to healthy subjects [8]. Here we show that the
percentage of cells expressing NOX4 is significantly
elevated in ASM from COPD versus asthmatic subjects
(4of the asthma subjects were included in our previ-
ous report [8]) (91 ± 1 % versus 72 ± 7 % respectively;
P = 0.046, Fig. 1e), although there was no difference in
the geometric mean fluorescence intensity. Following
treatment with 50 ng/ml TNFα for 24 h the geometric
mean fluorescence intensity of NOX4 expression was
significantly elevated in COPD (mean fold difference
[95 % CI] 1.32 [1.22–1.43]; P < 0.001), but not asthmatic
subjects (1.06-fold [0.93 to 1.21]; P = 0.29) (Fig. 1f).
ASM-derived from subjects with asthma, COPD and
healthy controls were stimulated with hydrogen peroxide
(10 mM). This concentration was chosen as a submaxi-
mal stimulus to promote ROS production without affect-
ing cell viability. Following hydrogen peroxide exposure,
there was an increase in the production of ROS by ASM
from subjects with COPD, asthma and healthy controls
(Fig. 1g). This increase was significantly greater in those
with asthma compared to healthy controls and COPD,
but was not different between COPD and health (Fig. 1g).
This oxidant-induced ROS production was abrogated by
the addition of NOX4 inhibitor (mean difference [95 %
CI] -496.3 [−647.7 to −344.9]; P = 0.0001; Fig. 1h).
We show for the first time that in vivo NOX4 expres-
sion is up-regulated in ASM from COPD subjects and
smokers with a >20 pack year history compared to
smokers with a ≤20 pack year smoking history, and posi-
tively correlates to pack year history. We show that the
percentage of NOX4 protein expression is significantly
increased in primary ASM cells from COPD subjects
compared to asthmatic subjects and that the intensity of
expression is increased in COPD ASM following activa-
tion by TNFα. Oxidant-induced ROS generation in ASM
from COPD subjects was similar to healthy control
ASM and less than ASM-derived from asthmatic sub-
jects. This oxidant-induced ASM ROS generation was
completely abrogated by NOX4 inhibition in those sub-
jects with or without COPD.
Oxidant/antioxidant imbalance is an important patho-
genic factor in COPD [9]. This imbalance may be a con-
sequence of environmental insults, the inflammatory
milieu in COPD or due to abnormalities in the dynamic
and complex processes involved in the generation and
detoxification of ROS. Few studies have addressed the
role of NOX4, Milara et al. showed that NOX4 expres-
sion and ROS generation are enhanced following expos-
ure of human bronchial epithelial cells to cigarette
smoke extract [13]. We have shown for the first time
that in vivo NOX4 protein expression in ASM is ele-
vated in COPD and controls with significant smoking
histories. In addition we found that NOX4 protein
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expression in ASM cells from COPD subjects was fur-
ther elevated compared to ASM from asthmatic sub-
jects, and that the intensity of this expression in ASM
from COPD subjects was enhanced in the presence of
TNFα, which is increased in COPD [11].
Basal levels of ROS generation were not different be-
tween ASM from healthy control, asthmatic and COPD
subjects. In contrast to the increase seen in asthma, the
amount of ROS generated following stimulation with
hydrogen peroxide using the DCFDA assay was similar
in ASM from COPD subjects and healthy controls.
Possible explanations for this apparent anomaly include
differential NOX4 activity or activation/suppression of
NOX4 independent pathways in the ASM derived from
COPD subjects versus healthy controls. NOX4 plays an
important role in the overall oxidative burden of the
ASM, as demonstrated by our data showing that H2O2
stimulated ROS production in ASM can be completely
abrogated with a NOX4 inhibitor. However the magni-
tude of this role in COPD needs to be further studied in
vivo. It has previously been shown that NOX4 up-
regulation and consequent ROS generation promote
TGF-β1-induced proliferation and hypertrophy of ASM
[14]. Whether up-regulation of NOX4 expression, and
the oxidative burden in COPD in vivo contribute to
ASM dysfunction in COPD subjects remains to be
determined.
Thus, we provide evidence for up-regulation of NOX4
expression in vivo and in vitro in the ASM from COPD
subjects and complete abrogation of oxidant-induced
ROS generation by NOX4 inhibition. The development
of NOX4 small molecule inhibitors in clinical trials for
other disease indications (NCT02010242) means that
the role of NOX4 in COPD could be tested in the clinic
in the near future.
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Fig. 1 a Example photomicrographs of ASM stained with (i) isotype control or (ii-iv) NOX4 in a healthy control with a less than or greater than 20
pack year history and subject with COPD respectively and (v) an example of a COPD subject with more intense staining at higher power. b NOX4
% positive staining assessed by thresholding (mean [SEM]). n = 6 (<20 pack years healthy controls), n = 4 (>20 pack years healthy controls), n = 9
(COPD). c Correlation between smoking history and NOX4 ASM expression. d NOX4 mRNA (measured in triplicate) in ASM from COPD versus
healthy controls. n = 11 (healthy controls), n = 9 (COPD). e Percentage of cells expressing NOX4 in ASM from COPD and asthma subjects assessed
by flow cytometry. n = 7 (asthma), n = 5 (COPD). f Geometric mean fluorescence intensity of NOX4 expression following incubation with control
media or 50 ng/mL TNFα in ASM from subjects with COPD or asthma. n = 7 (asthma), n = 5 (COPD). g Detection of intracellular ROS (measured in
triplicate; relative fluorescent units [RFU]) in ASM induced by hydrogen peroxide. n = 9 (healthy controls), n = 5 (asthma), n = 5 (COPD). h Detection
of hydrogen peroxide-induced intracellular ROS following pre-incubation with NOX4 inhibitor. n = 10. Each point represents an individual donor:
circles-healthy, square-COPD and triangle-asthma subjects
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